$63.8 million settlement in Paxil class action
A judge deemed a $63.8 million settlement fair and reasonable for a class-action suit against GlaxoSmith Klein, the makers of Paxil and Paxil CR.
The lawsuit claimed GlaxoSmithKline promoted the drugs while withholding negative information about the drugs' safety and effectiveness. Paxil is usually used to treat depression and anxiety for children and teens. Members of this class action lawsuit included all U.S. residents who bought Paxil for their children.
Consumers who have records of their purchases can get full refunds for their expenditures.
The objections to the settlement were withdrawn prior to the fairness hearing after modifications were made. Those modifications included: Consumers who do not have records can get $100; the $300,000 cap for undocumented claims was eliminated; and the $16.6 million for attorney fees will be distributed to attorneys who have also done work to benefit the class-action suit other than the plaintiff attorneys.
http://www.belleville.comhttp://www.belleville.com/179/story/21022.html